Sarepta Therapeutics (SRPT) Receivables (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Receivables of $531.2 million for Q1 2026, down 25.66% year-over-year from $714.6 million in Q1 2025, and up 5.76% quarter-over-quarter from $502.3 million in Q4 2025.
Sarepta Therapeutics (SRPT) Receivables (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $531.2 million for Q1 2026.
- In Q1 2026, Receivables fell 25.66% year-over-year to $531.2 million; the TTM figure through Mar 2026 stood at $531.2 million (down 25.66% YoY), while the FY2025 annual figure was $502.3 million, down 21.09% from the prior year.
- Receivables for Q1 2026 stood at $531.2 million, up from $502.3 million in the prior quarter.
- The five-year high for Receivables was $714.6 million in Q1 2025, with the low at $195.9 million in Q1 2022.
- The 5-year median for Receivables is $408.9 million (2024), against an average of $411.9 million.
- The sharpest annual moves came in 2023 and 2026: Receivables jumped 97.39% in 2023, then declined 25.66% in 2026.
- Sarepta Therapeutics' Receivables stood at $217.9 million in 2022, then surged by 97.39% to $430.1 million in 2023, then jumped by 48.0% to $636.6 million in 2024, then dropped by 21.09% to $502.3 million in 2025, then gained by 5.76% to $531.2 million in 2026.
- Business Quant data shows SRPT's Receivables at $531.2 million in Q1 2026, $502.3 million in Q4 2025, and $524.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 421.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 421.82 Mn |
| Mar 31, 2026 | 531.22 Mn |
| Dec 31, 2025 | 502.30 Mn |
| Sep 30, 2025 | 524.44 Mn |
| Jun 30, 2025 | 600.60 Mn |
| Mar 31, 2025 | 714.60 Mn |
| Dec 31, 2024 | 636.59 Mn |
| Sep 30, 2024 | 500.92 Mn |
| Jun 30, 2024 | 379.90 Mn |
| Mar 31, 2024 | 408.91 Mn |
| Dec 31, 2023 | 430.13 Mn |
| Sep 30, 2023 | 354.30 Mn |
| Jun 30, 2023 | 265.41 Mn |
| Mar 31, 2023 | 285.84 Mn |
| Dec 31, 2022 | 217.91 Mn |
| Sep 30, 2022 | 223.41 Mn |
| Jun 30, 2022 | 230.30 Mn |
| Mar 31, 2022 | 195.90 Mn |
| Dec 31, 2021 | 153.00 Mn |
| Sep 30, 2021 | 178.42 Mn |